Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,121 to 3,140 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Alirocumab 150 mg Q2W vs Placebo Q2W: serious adverse events | 290 of 1,550 154 of 788 | -0.8 points -4.3 to 2.5 | 2,338 | NCT01507831 Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term) |
| Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections vs Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections: Number of Participants With Virologically Confirmed Cases of ZIKV (Part B Only) | 1 of 1,170 2 of 1,168 | -0.1 points -0.5 to 0.3 | 2,338 | NCT03110770 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents |
| Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections vs Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections: Number of Participants With Subclinical Cases of ZIKV (Part B Only) | 1 of 1,170 0 of 1,168 | 0.1 points -0.2 to 0.5 | 2,338 | NCT03110770 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents |
| Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography | 209 of 1,157 220 of 1,178 | -0.6 points -3.8 to 2.5 | 2,335 | NCT02173379 Absorb IV Randomized Controlled Trial |
| TDF/FTC vs Placebo: Incidence of Confirmed Syphilis During Follow-Up | 147 of 1,155 132 of 1,171 | 1.5 points -1.2 to 4.1 | 2,326 | NCT00458393 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men |
| Folic Acid 4 mg vs Placebo: Preterm Birth | 297 of 1,150 304 of 1,164 | -0.3 points -3.9 to 3.3 | 2,314 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Incentives vs Usual Care: deaths from any cause | 104 of 1,114 125 of 1,200 | -1.1 points -3.5 to 1.4 | 2,314 | NCT02969915 Strategies to Improve the HIV Care Continuum Among Key Populations in India |
| Incentives vs Usual Care: serious adverse events | 104 of 1,114 125 of 1,200 | -1.1 points -3.5 to 1.4 | 2,314 | NCT02969915 Strategies to Improve the HIV Care Continuum Among Key Populations in India |
| Fosaprepitant vs Aprepitant: serious adverse events | 148 of 1,143 157 of 1,169 | -0.5 points -3.2 to 2.3 | 2,312 | NCT00619359 Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) |
| Cervarix Group vs Placebo Group: Number of Subjects With Unsolicited Adverse Events for Subjects Seropositive and/or DNA Positive for Either HPV-16 or HPV-18 at Baseline | 295 of 1,131 307 of 1,179 | 0.0 points -3.5 to 3.6 | 2,310 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| Cervarix Group vs Placebo Group: Number of Subjects With Medically Significant Conditions Regardless of Causal Relationship to Vaccination and Intensity for Subjects Seropositive and/or DNA Positive for Either HPV-16 or HPV-18 at Baseline | 64 of 1,131 75 of 1,179 | -0.7 points -2.7 to 1.3 | 2,310 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| Aspirin vs Warfarin: serious adverse events | 617 of 1,163 632 of 1,142 | -2.3 points -6.3 to 1.8 | 2,305 | NCT00041938 Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial |
| Q/LAIV (MEDI3250) vs All FluMist Group: serious adverse events | 6 of 1,382 5 of 923 | -0.1 points -0.9 to 0.5 | 2,305 | NCT01091246 A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children |
| Wearable Defibrillator vs Conventional Treatment: Sudden Death Mortality | 25 of 1,524 19 of 778 | -0.8 points -2.2 to 0.4 | 2,302 | NCT01446965 Vest Prevention of Early Sudden Death Trial and VEST Registry |
| Wearable Defibrillator vs Conventional Treatment: All Cause Mortality | 48 of 1,524 38 of 778 | -1.7 points -3.6 to -0.1 | 2,302 | NCT01446965 Vest Prevention of Early Sudden Death Trial and VEST Registry |
| Wearable Defibrillator vs Conventional Treatment: deaths from any cause | 48 of 1,524 38 of 778 | -1.7 points -3.6 to -0.1 | 2,302 | NCT01446965 Vest Prevention of Early Sudden Death Trial and VEST Registry |
| Wearable Defibrillator vs Conventional Treatment: serious adverse events | 475 of 1,524 253 of 778 | -1.4 points -5.4 to 2.6 | 2,302 | NCT01446965 Vest Prevention of Early Sudden Death Trial and VEST Registry |
| Transdisciplinary Approach vs Multidisciplinary Approach: Behavioral Symptoms | 104 of 648 299 of 1,654 | -2.0 points -5.3 to 1.5 | 2,302 | NCT03442322 Optimizing Care for Patients With Dementia |
| Folic Acid 4 mg vs Placebo: Preeclampsia | 169 of 1,144 156 of 1,157 | 1.3 points -1.6 to 4.1 | 2,301 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Transdisciplinary Approach vs Multidisciplinary Approach: Rejection of Care | 75 of 648 282 of 1,653 | -5.5 points -8.4 to -2.3 | 2,301 | NCT03442322 Optimizing Care for Patients With Dementia |
Code
curl "https://conductscience.org/api/comparisons/v1?page=157"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=157
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01507831-sae",
"title": "Alirocumab 150 mg Q2W vs Placebo Q2W: serious adverse events",
"summary": "290 of 1550 against 154 of 788; risk difference -0.8 points, 95% interval -4.3 to 2.5; NCT01507831, Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)",
"record": "/library/comparisons/NCT01507831-sae",
"nct_id": "NCT01507831",
"kind": "serious-adverse-events",
"participants": 2338,
"risk_difference": {
"value": -0.008334697887669884,
"lower": -0.042919187632066036,
"upper": 0.024720830762770235
},
"group_1": "290 of 1,550",
"group_2": "154 of 788",
"difference": "-0.8 points",
"interval": "-4.3 to 2.5",
"trial_title": "Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)"
},
{
"id": "NCT03110770-5dff3b50",
"title": "Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections vs Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections: Number of Participants With Virologically Confirmed Cases of ZIKV (Part B Only)",
"summary": "1 of 1170 against 2 of 1168; risk difference -0.1 points, 95% interval -0.5 to 0.3; NCT03110770, VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents",
"record": "/library/comparisons/NCT03110770-5dff3b50",
"nct_id": "NCT03110770",
"kind": "outcome",
"participants": 2338,
"risk_difference": {
"value": -0.0008576279124224329,
"lower": -0.005421752703196649,
"upper": 0.003303034155876399
},
"group_1": "1 of 1,170",
"group_2": "2 of 1,168",
"difference": "-0.1 points",
"interval": "-0.5 to 0.3",
"trial_title": "VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=158",
"request_id": "QOpjtUAoGCoO_X0_"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant